NKTR Earnings & Financial Statements
Nektar Therapeutics
$36.89
-$1.03(-2.72%)
30
Overall
40
Value
9
Tech
42
Quality
Market Cap
$1.26B
Volume
999.60K
52W Range
$33.40 - $109.00
Target Price
$132.73
NKTR earnings and financial statements: Nektar Therapeutics's income statement, balance sheet and cash flow statement, annual and quarterly.
NKTR Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $55.23M | $98.43M | $90.12M | $92.06M | $101.91M |
| Cost of revenue | - | $30.69M | $33.77M | $21.64M | $24.90M |
| Operating income | -$140.10M | -$105.20M | -$263.68M | -$376.17M | -$446.10M |
| EBITDA | -$168.70M | -$124.05M | -$283.30M | -$323.04M | -$461.82M |
| Net income | -$164.08M | -$118.96M | -$276.06M | -$368.20M | -$523.84M |
| EPS (diluted) | $-9.73 | $-8.70 | $-21.75 | $-29.55 | $-42.90 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $280.41M | $303.85M | $398.03M | $710.60M | $1.12B |
| Total liabilities | $190.57M | $243.11M | $267.05M | $343.96M | $437.68M |
| Shareholders’ equity | $89.83M | $60.74M | $130.99M | $366.64M | $679.51M |
| Cash and equivalents | $15.12M | $44.25M | $35.28M | $88.23M | $25.22M |
| Long-term debt | $65.26M | $82.70M | $98.52M | $112.83M | $125.74M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$208.51M | -$175.71M | -$192.61M | -$304.01M | -$412.66M |
| Capital expenditure | -$171.0K | -$1.47M | -$865.0K | -$5.68M | -$14.99M |
| Free cash flow | -$208.68M | -$177.18M | -$193.47M | -$309.68M | -$427.65M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NKTR | $36.89 | -2.7% | 999.60K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |